研究者詳細 - 豊岡　伸一

論文 - 豊岡　伸一

分割表示 939 件中 221 - 240 件目／全件表示 >>

本邦における肺移植時の一酸化窒素ガス(NO)使用状況に関する実態調査

吉安展将, 佐藤雅昭, 中島大輔, 富岡泰章, 渡辺有為, 白石武史, 舟木壮一郎, 前田寿美子, 朝重耕一, 中島崇裕, 土谷智史, 杉本誠一郎, 吉野一郎, 永安武, 千田雅之, 南正人, 岡田克典, 豊岡伸一, 伊達洋至, 中島淳

移植 56 ( 1 ) 88 - 88 2021年7月

BKウイルス感染症による出血性膀胱炎で周術期治療に難渋した小児生体肺移植の1例

富岡泰章, 大谷真二, 石上恵美, 石原恵, 松原慧, 清水大, 山本治慎, 塩谷俊雄, 三好健太郎, 岡崎幹生, 杉本誠一郎, 山根正修, 豊岡伸一

移植 56 ( 1 ) 100 - 100 2021年7月

"Hybrid Lung Transplantation" Combining Living Donor and Cadaveric Lung Transplants: Report of 2 Cases. 国際誌

Takeshi Kurosaki, Takahiro Oto, Shinji Otani, Kentaroh Miyoshi, Seiichiro Sugimoto, Masaomi Yamane, Shinichi Toyooka

Transplantation proceedings 2021年6月

記述言語：英語掲載種別：研究論文（学術雑誌）

We present 2 cases of "hybrid lung transplant," which included sequentially implanting a living lobar graft to 1 side and a cadaveric graft to the other side. This procedure was approved by the institutional review board at Okayama University Hospital. The 2 recipients were diagnosed with severe idiopathic pulmonary fibrosis, and living donor lobar lung transplant was considered; however, 2 appropriate donors were not available. Therefore, we accepted extended criteria donor lungs with a partial pressure of oxygen/fraction of inspired oxygen ratio of <251 mm Hg. However, 1 of the 2 patients developed grade 2 primary graft dysfunction. The living donor lobar lung had a low volume but was in good condition, which contributed to the patient's recovery after primary graft dysfunction during the perioperative period. The other patient's status of bronchiolitis obliterans syndrome had gradually progressed to grade 3, and only the living donor lung was functioning at that time. However, both patients are alive 5.5 and 4.2 years after lung transplant, respectively. Hybrid lung transplantation may increase patients' chances of receiving transplants because patients are not likely to survive while waiting for ideal donor lungs to become available.

DOI： 10.1016/j.transproceed.2021.04.019

PubMed

researchmap

Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: a retrospective analysis. 国際誌

Kuniaki Katsui, Takeshi Ogata, Soichi Sugiyama, Kotaro Yoshio, Masahiro Kuroda, Takao Hiraki, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa

Scientific reports 11 ( 1 ) 11882 - 11882 2021年6月

記述言語：英語掲載種別：研究論文（学術雑誌）

We intended to investigate whether muscle and adipose masses were associated with prognosis among patients with stage III non-small-cell lung cancer (NSCLC) who were undergoing chemoradiotherapy (CCRT). We retrospectively explored data of patients with stage III NSCLC who underwent definitive CCRT (≥ 60 Gy) between January 2004 and March 2018 at our hospital. We examined the relationship of overall survival (OS) with body mass index (BMI), skeletal muscle index (SMI), psoas muscle index (PMI), visceral adipose tissue index (VAI), subcutaneous adipose tissue index (SAI), and visceral-to-subcutaneous adipose tissue area ratio (VSR) using log-rank tests for the univariate analysis and Cox proportional hazard models for the multivariate analysis. Overall, 16, 32, and 12 patients had stage IIIA, IIIB, and IIIC NSCLC, respectively. The total radiotherapy dose ranged from 60 Gy/30 fractions to 66 Gy/33 fractions. In the univariate analysis, the performance status (PS), BMI, and SMI were associated with OS, whereas the PMI, VAI, SAI, and VSR were not. In the multivariate analysis, the PS and SMI were associated with OS. The hazard ratios and 95% confidence intervals were 2.91 and 1.28-6.64 for PS, and 2.36 and 1.15-4.85 for SMI, respectively. The 1, 3, and 5-year OS rates were 92.1%, 59.6%, and 51.0% in patients with high SMI, and 63.6%, 53.8%, and 17.9% in patients with low SMI, respectively. The SMI correlated with prognosis in our study population, whereas adipose mass did not. Therefore, sarcopenia should be considered while predicting the OS in such patients.

DOI： 10.1038/s41598-021-91449-z

PubMed

researchmap

Clinical Outcome of Palliative Concurrent Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-small Cell Lung Cancer.

Kuniaki Katsui, Takeshi Ogata, Kenta Watanabe, Kotaro Yoshio, Masahiro Kuroda, Takao Hiraki, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa

Acta medica Okayama 75 ( 3 ) 269 - 277 2021年6月

記述言語：英語掲載種別：研究論文（学術雑誌）

Palliative concurrent chemoradiotherapy (CCRT) is often administered to patients with stage III non-small cell lung cancer (NSCLC). We investigated the clinical outcomes of patients receiving palliative CCRT for NSCLC. Data of patients with NSCLC who underwent palliative CCRT (n=16), preoperative CCRT plus surgery (n=97), or definitive CCRT (n=48) were evaluated. In all groups, the concurrent chemotherapy regimens consisted of cisplatin and docetaxel. Rates of local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS), overall survival (OS), and prognosis were compared. The 2-year rates of LC, DMFS, PFS, and OS in 16 patients who underwent palliative CCRT were 44.4%, 12.5%, 12.5%, and 18.8%, respectively. Univariate analysis showed that palliative CCRT was associated with poor LC (p<0.001), DMFS (p<0.001), PFS (p<0.001), and OS (p<0.001) outcomes in patients who completed CCRT as a preoperative treatment and poor LC (p=0.01), DMFS (p=0.003), PFS (p=0.04), and OS (p=0.004) outcomes in patients who were considered for definitive CCRT. Although there were some long-term survivors, the clinical outcomes of palliative CCRT were significantly inferior to those of the ideal treatments. Therefore, careful determination of the appropriate treatment indications and further studies are warranted.

DOI： 10.18926/AMO/62218

PubMed

researchmap

Robot-assisted intrathoracic procedure for dumbbell tumour in the prone position

Mikio Okazaki, Tomoyuki Takigawa, Ken Suzawa, Shinichi Toyooka

Interactive CardioVascular and Thoracic Surgery 2021年5月

掲載種別：研究論文（学術雑誌）出版者・発行元：Oxford University Press (OUP)

<title>Abstract</title>
A 24-year-old man presented with a dumbbell-shaped right posterior mediastinal mass. The patient was placed in the prone position following general anaesthesia and intubation. After laminectomy and dissection of the dorsal part of the tumour using a posterior approach were performed, the tumour was completely resected using a robotic approach in the thoracic cavity without repositioning. This is the first report of robotic resection for posterior mediastinal tumour in the prone position as well as a novel combined posterior approach and robotic resection for dumbbell tumours.

DOI： 10.1093/icvts/ivab117

researchmap

Circulating anti-human leukocyte antigen IgM antibodies as a potential early predictor of allograft rejection and a negative clinical outcome after lung transplantation.

Kazuaki Miyahara, Kentaroh Miyoshi, Takeshi Kurosaki, Shinji Otani, Seiichiro Sugimoto, Masaomi Yamane, Shinichi Toyooka

Surgery today 2021年5月

記述言語：英語掲載種別：研究論文（学術雑誌）

PURPOSE: Anti-human leukocyte antigen (HLA) immunoglobulin (Ig) M production stimulated by an alloantigen is sensitive, making IgM a novel potential marker of allorejection after organ transplantation. This study examined the relationship between the serum levels of anti-HLA IgM early after clinical lung transplantation (LTx) and the post-transplant outcomes. METHODS: Thirty-one consecutive patients who underwent deceased LTx were included. Immunoreactivity against HLA was retrospectively analyzed by measuring the anti-HLA IgM levels in the serum sampled for the first 14 days after LTx. The flow panel reactive antibody technique was used. The ratio of the anti-class I IgM level at each day to baseline was obtained, and the peak IgM level was determined for each case. The correlation between the peak IgM level and subsequent development of acute rejection (AR), chronic lung allograft dysfunction (CLAD), and survival outcomes were examined. RESULTS: The peak IgM level was a significant risk factor for AR within 90 days in univariate and multivariate analyses. In the long term, the patients with positive IgM (peak level > 1.8) tended to have a poorer CLAD-free and overall survival than those with negative IgM. CONCLUSION: Elevation of anti-HLA IgM levels early after LTx may be correlated with a higher incidence of rejection and negative clinical outcomes.

DOI： 10.1007/s00595-021-02293-7

PubMed

researchmap

Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301. 国際誌

Norihito Okumura, Junichi Soh, Hiroyuki Suzuki, Masao Nakata, Toshiya Fujiwara, Hiroshige Nakamura, Makoto Sonobe, Takuji Fujinaga, Kazuhiko Kataoka, Kenichi Gemba, Masafumi Kataoka, Katsuyuki Hotta, Hiroshige Yoshioka, Keitaro Matsuo, Junichi Sakamoto, Hiroshi Date, Shinichi Toyooka

BMC cancer 21 ( 1 ) 506 - 506 2021年5月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: The aim of this multicenter, randomized phase II study was to analyze the feasibility and safety of alternate-day S-1, an oral fluoropyrimidine, for adjuvant chemotherapy in patients with completely resected pathological stage I (tumor diameter > 2 cm) non-small cell lung cancer (NSCLC). METHODS: Patients were randomly assigned to receive adjuvant chemotherapy for 1 year comprising either alternate-day oral administration of S-1 (80 mg/m2/day) for 4 days a week (Group A) or a 2-week oral administration of S-1 (80 mg/m2/day) followed by 1 week of rest (Group B). The primary endpoint was feasibility, which was defined as the proportion of patients who completed the allocated intervention for 6 months with a relative dose intensity (RDI) of 70% or more. RESULTS: Ninety-three patients were enrolled of whom 90 patients received S-1 treatment. Median follow-up was 66.9 months. The treatment completion rate based on an RDI of 70% or more for 6 months was 84.4% (95%CI; 70.5-93.5%) in group A and 64.4% (95%CI; 48.8-78.1%) in group B. There were no grade 4 adverse events in either group. Moderate or severe adverse events (grade 2 or grade 3) were significantly more frequent in group B (67%) compared with group A (29%, P = 0.001). The 5-year relapse-free survival rate was 87.0 and 80.9% for group A and B, respectively (P = 0.451). The 5-year overall survival rate for all patients (n = 93) was 100 and 89.4% for group A and B, respectively (P = 0.136). CONCLUSION: Alternate-day oral administration of S-1 for 1 year as adjuvant chemotherapy was demonstrated to be feasible with low toxicity in completely resected stage I (tumor diameter > 2 cm) NSCLC. TRIAL REGISTRATION: Trial registration number: UMIN000011994 . Date of registration: 10/8/2013.

DOI： 10.1186/s12885-021-08232-6

PubMed

researchmap

Best practices for the extraction of genomic DNA from formalin-fixed paraffin-embedded tumor tissue for cancer genomic profiling tests. 国際誌

Hirofumi Inoue, Shuta Tomida, Shigeru Horiguchi, Hironari Kato, Hiromi Matsuoka, Etsuko Sanehira, Masashi Matsuoka, Hiroyuki Yanai, Akira Hirasawa, Shinichi Toyooka

Pathology international 71 ( 5 ) 360 - 364 2021年5月

記述言語：英語掲載種別：研究論文（学術雑誌）

Recently, two cancer genomic profiling tests have been approved in Japan and implemented in routine clinical practice: the FDA-approved FoundationOne CDx test, and the OncoGuide NCC Oncopanel test. The quality and quantity of DNA significantly affects the sequencing results; therefore, preparing a sufficient amount of high-quality DNA for clinical cancer genomic profiling tests is important. We examined the best practices for the extraction of cancer genomic DNA from formalin-fixed paraffin-embedded (FFPE) tumor tissues of pancreatic, lung and colon cancer specimens. We found that the quality of cancer genomic DNA extracted from 10-μm-thick FFPE samples improved significantly, compared with that from 4-μm-thick FFPE samples, suggesting that 10-μm-thick FFPE samples are preferable for clinical cancer genomic profiling tests. For convenience, we created a quick reference table for calculating the required number of FFPE slides.

DOI： 10.1111/pin.13086

PubMed

researchmap

RATS? VATS? Uniportal VATS?〜あなたならどのアプローチを選ぶ?〜肥満症例や不全分葉症例から見たRATSの有用性

岡崎幹生, 諏澤憲, 三好健太郎, 大谷真二, 山本寛斉, 杉本誠一郎, 山根正修, 豊岡伸一

日本呼吸器外科学会雑誌 35 ( 3 ) PD3 - 3 2021年5月

N2肺癌に対する免疫チェックポイント阻害剤を用いた周術期治療の可能性 WJOG12119L試験

濱田顕, 宗淳一, 大泉弘幸, 坪井正博, 堀之内秀仁, 吉野一郎, 棚橋雅幸, 豊岡伸一, 岡田守人, 横見瀬裕保, 山下素弘, 光冨徹哉

日本呼吸器外科学会雑誌 35 ( 3 ) S - 5 2021年5月

肺移植患者の周術期におけるClostridioides difficile感染症の検討

坂田龍平, 大谷真二, 石上恵美, 石原恵, 土生智大, 岩田一馬, 久保友次郎, 松田直樹, 清水大, 松原慧, 富岡泰章, 山本治慎, 塩谷俊雄, 三好健太郎, 岡崎幹生, 杉本誠一郎, 山根正修, 豊岡伸一

日本呼吸器外科学会雑誌 35 ( 3 ) O18 - 4 2021年5月

肺移植における最適な術前予後予測スコアリング法 9つの術前予後予測スコアリング法の検証から

山本治慎, 杉本誠一郎, 富岡泰章, 塩谷俊雄, 清水大, 松原慧, 三好健太郎, 大谷真二, 岡崎幹生, 山根正修, 豊岡伸一

日本呼吸器外科学会雑誌 35 ( 3 ) O18 - 5 2021年5月

N2肺癌に対する術前導入化学放射線療法後手術症例における好中球/リンパ球比の検討

山本寛斉, 津高慎平, 富岡泰章, 塩谷俊雄, 諏澤憲, 三好健太郎, 大谷真二, 岡崎幹生, 杉本誠一郎, 山根正修, 豊岡伸一

日本呼吸器外科学会雑誌 35 ( 3 ) O8 - 1 2021年5月

肺移植後移植片慢性機能不全におけるGoddard scoreの検討

塩谷俊雄, 杉本誠一郎, 山本治慎, 富岡泰章, 諏澤憲, 三好健太郎, 大谷真二, 山本寛斉, 岡崎幹生, 山根正修, 豊岡伸一

日本呼吸器外科学会雑誌 35 ( 3 ) O18 - 3 2021年5月

肺がん治療発展を目指した呼吸器外科医の役割家族性肺がんの経験

諏澤憲, 山本寛斉, 三好健太郎, 大谷真二, 岡崎幹生, 杉本誠一郎, 山根正修, 豊岡伸一

日本呼吸器外科学会雑誌 35 ( 3 ) MO10 - 3 2021年5月

ロボット支援手術第2世代術者のラーニングカーブ

大谷真二, 岡崎幹生, 坂田龍平, 松田直樹, 岩田一馬, 高津史明, 諏澤憲, 三好健太郎, 山本寛斉, 杉本誠一郎, 山根正修, 豊岡伸一

日本呼吸器外科学会雑誌 35 ( 3 ) MO58 - 1 2021年5月

UNCX遺伝子多型と肺移植後の腎機能障害との関係

富岡泰章, 杉本誠一郎, 山本治慎, 清水大, 松原慧, 塩谷俊雄, 諏澤憲, 三好健太郎, 大谷真二, 山本寛斉, 岡崎幹生, 山根正修, 豊岡伸一

日本呼吸器外科学会雑誌 35 ( 3 ) RO17 - 2 2021年5月

Vessel sealerを常時用いたRATS手技

岡崎幹生, 諏澤憲, 大谷真二, 三好健太郎, 山本寛斉, 杉本誠一郎, 山根正修, 豊岡伸一

日本呼吸器外科学会雑誌 35 ( 3 ) RV5 - 1 2021年5月

肺移植における予後改善に向けての取組生体肺移植と脳死肺移植の違いに着目した慢性移植肺機能不全(CLAD)の早期診断を目指した取り組み

杉本誠一郎, 塩谷俊雄, 山本治慎, 富岡泰章, 諏澤憲, 三好健太郎, 大谷真二, 山本寛斉, 岡崎幹生, 山根正修, 豊岡伸一

日本呼吸器外科学会雑誌 35 ( 3 ) PD2 - 4 2021年5月

　前のページ - 次のページ　

<豊岡 伸一>

論文 - 豊岡 伸一

<豊岡　伸一>

論文 - 豊岡　伸一